President Donald Trump signed a significant executive order on December 18, 2025. This order makes major changes to federal cannabis policy. It directs the Justice Department to expedite marijuana’s rescheduling. Marijuana moves from Schedule I to Schedule III of the Controlled Substances Act. This is a historic shift. It eases restrictions on medical research. It also aims to help the struggling hemp industry. Furthermore, the order includes provisions for Medicare coverage of certain CBD treatments. These cannabis events are trending news across the nation.
Cannabis Rescheduling to Schedule III
The move reclassifies marijuana. It becomes a Schedule III substance. This places it alongside drugs like ketamine. Previously, it was a Schedule I drug. Schedule I is for substances with high abuse potential. It also has no accepted medical use. Rescheduling to Schedule III recognizes its medical applications. This change will make research easier. It can unlock billions in research funding. It also offers potential tax breaks for businesses. The industry faces significant tax burdens. This rescheduling could alleviate some of that pressure. It may attract wary investors too. However, rescheduling does not legalize marijuana federally. It also does not decriminalize it nationwide. The DEA must still complete its review process. Some Republicans still oppose these changes. They urged the president to maintain current standards.
Expanding Medicare Coverage for CBD
The executive order introduces a new Medicare pilot program. This program will allow eligible beneficiaries to receive hemp-derived CBD products. These products will be covered at no cost. This requires a recommendation from a licensed physician. Products must meet state safety standards. They must also come from legally compliant hemp sources. Third-party lab testing is required. This initiative is a historic step. It provides federally supported access to cannabinoid therapies. Seniors may particularly benefit. This could help manage pain and other conditions. Dr. Mehmet Oz, head of CMS, announced the model.
Support for the Hemp Industry
The order also addresses the hemp industry. It aims to revise the legal definition of hemp. This seeks to better support full-spectrum CBD products. Recent legislation limited THC content in hemp products. This effectively banned many full-spectrum options. The new directive pushes for an updated definition. This offers a lifeline to hemp farmers and businesses. It could mitigate uncertainty from conflicting regulations.
Public Opinion and Political Context
These policy shifts reflect growing public support. A poll from a conservative group showed most Americans favor legalization. However, opinions are divided among certain demographics. Most older Trump voters oppose legalization. Younger Trump voters showed more support. While states have moved towards legalization, federal policy lagged. This executive order marks a significant change in federal posture. It follows years of discussion and advocacy.
Ongoing Cannabis Banking Debates
The issue of banking access for cannabis businesses remains critical. This executive order does not directly address banking. The SAFE Banking Act is a key piece of legislation. Senators have discussed it in committee hearings. Senator Catherine Cortez Masto champions the bill. She notes that rescheduling alone does not solve banking problems. Many cannabis companies still operate mostly in cash. This creates safety and compliance issues. The SAFE Banking Act aims to protect financial institutions. It would offer a safe harbor for serving state-legal cannabis businesses.
Industry Trends and Challenges
The U.S. cannabis industry has faced contraction. Data shows a significant drop in cultivation permits. Active cannabis business licenses have also declined. This suggests an end to unchecked growth. Moving cannabis to Schedule III could boost the industry. It might attract more investors. However, significant questions remain. The future impact is still unfolding.
State-Level Progress: Maine
Marijuana is already legal for recreational and medical use in Maine. Adults 21 and older can possess up to 2.5 ounces. They can also cultivate a limited number of plants. Public consumption and driving under the influence are illegal in Maine. This state-level progress contrasts with federal policy history.
What’s Next?
While the executive order is signed, further steps are needed. The DEA will review the rescheduling recommendation. The Medicare CBD pilot program is set to begin soon. The industry watches these developments closely. Future legislative actions will shape the landscape further. These events are important news for the trending cannabis sector. The administration emphasizes this is about medical benefits. It aims to safeguard public health while promoting access.
